PAREXEL International

PAREXEL is a public Core Company formed as a global, full service Contract Research Organization (CRO) specializing in comprehensive clinical trials management, biostatistical consultation, patient recruitment, and regulatory submissions for pharmaceutical, biotechnology, medical device, and other health related industries. Public since November, 1995 (Nasdaq: PRXL).

Related News

UnitedHealth’s Optum and PAREXEL team up to improve drug post-approval studies

01.21.16

UnitedHealth's Optum and PAREXEL team up to improve drug post-approval studies Read Full Release

PAREXEL International, Corp. Reports Fourth Quarter and Fiscal Year 2014 Results

08.08.14

PAREXEL International Corp. reports a 10.2% growth in consolidated service revenue to $510.6 million for Q42013 and an 11.8% growth in consolidated service revenue to $1.94 billion for the Fiscal Year 2014. Read Full Release

PAREXEL International Reports Second Quarter Fiscal Year 2014 Results

01.29.14

PAREXEL International Second Quarter Fiscal Year 2014 Results were announced and for the three months ended December 31, 2013 consolidated service revenue increased by 15.4% to $487.1 million. Read Full Release

PAREXEL International Reports Fourth Quarter And Fiscal Year 2013 Results

08.08.13

PAREXEL International Corp. (NASDAQ: PRXL) reported financial results for the fourth quarter and Fiscal Year 2013. For the three months ended June 30, 2013 consolidated service revenue increased by 18% to $463.1 million compared with $392.6 million in the prior year period. Read Full Release